M4MM

Week In Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES - Critical compliance issues, market exits, and clinical and regulatory breakthroughs shaped a turbulent week for cannabis and psychedelics businesses. Cannabis Industry Highlights 1.Cresco Labs Exits California, Refocuses on Profitability Cresco Labs confirmed ...

Canada’s Cannabis Industry Defies Economic Odds

TORONTO – In a striking contrast to Canada’s faltering economy, the legal Cannabis industry continues to flourish, bolstering the nation’s GDP while other sectors struggle. Statistics Canada reports that the licensed cannabis sector grew by ...

Health Canada Approves Jazz Pharmaceuticals’ Epidiolex

NEW YORK- Canada's federal health regulator, Health Canada, has recently approved Epidiolex, a cannabinoid-based medicine developed by Jazz Pharmaceuticals Canada. This approval positions Epidiolex as a supplementary therapy for certain rare and severe forms of ...

Arkansas and Rhode Island Cannabis Markets

LOS ANGELES- October 2023 witnessed a modest reduction in medical cannabis sales in Arkansas, reaching $22.5 million, a slight decrease from the same period in 2022. This data, sourced from the state's Department of Finance ...

Algernon Pharmaceuticals Partners with Seyltx Inc.

LOS ANGELES- Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, has announced a significant advancement in its research program. The company has signed a Letter of Intent (LOI) with Seyltx Inc., a U.S.-based ...

Optimi Health Obtains Key Amendment to Dealer’s Licence

LOS ANGELES- Optimi Health, a Canadian company specializing in psychedelic drug research and formulation, has achieved a significant milestone with Health Canada's approval of an amendment to its Dealer's Licence. This crucial development allows Optimi ...

Subscribe To Our Newsletter